PHAT
Phathom Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.01
+1.30%Oct 8, 2026, 12:00 UTC
Phathom Pharmaceuticals announced that it will present three analyses of VOQUEZNA at the American College of Gastroenterology 2026 Annual Scientific Meeting, covering real-world patient characteristics, efficacy across BMI subgroups and cost-effectiveness in erosive esophagitis.
Source:Sep 29, 2026, 12:00 UTC
Phathom Pharmaceuticals initiated patient screening in the registrational Phase 3 pHalcon-NERD-302 study evaluating as-needed VOQUEZNA (vonoprazan) tablets in adults with Non-Erosive GERD.
Source:Sep 9, 2026, 15:48 UTC
Phathom Pharmaceuticals presented at the Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, highlighting rapid revenue growth and its first quarterly operating profit excluding stock-based compensation.
Source:Jul 31, 2026, 14:07 UTC
SueWallSt notified investors of potential securities claims involving Phathom Pharmaceuticals, related to the company's full-year revenue guidance.
Source:Jul 30, 2026, 10:59 UTC
Phathom Pharmaceuticals reported financial results for the second quarter ended June 30, 2026.
Source:Jun 23, 2026, 11:59 UTC
Phathom Pharmaceuticals completed patient enrollment in its Phase 2 pHalcon-EoE-201 clinical trial of VOQUEZNA (vonoprazan) for eosinophilic esophagitis.
Source: